ArticleMedical oncology (Northwood, London, England)2015
MicroRNA-29s could target AKT2 to inhibit gastric cancer cells invasion ability.
Article in Medical oncology (Northwood, London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 23 citations in OpenAlex.
- [High expression of CRTAC1 promotes proliferation, migration and immune cell infiltration of gastric cancer by regulating the PI3K/AKT signaling pathway].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024Article
- Article
- Case report: Cytokine and miRNA profiling in multisystem inflammatory syndrome in children.Frontiers in medicine · 2024Article
- Small molecules with huge impacts: the role of miRNA-regulated PI3K pathway in human malignancies.Molecular biology reports · 2021Review
- KLF5 activates lncRNA DANCR and inhibits cancer cell autophagy accelerating gastric cancer progression.NPJ genomic medicine · 2021Article
- MicroRNA-29b-3p suppresses oral squamous cell carcinoma cell migration and invasion via IL32/AKT signalling pathway.Journal of cellular and molecular medicine · 2020Article
- Tumor promoter role of miR‑647 in gastric cancer via repression of TP73.Molecular medicine reports · 2018Article
- MiR-29c reduces the cisplatin resistance of non-small cell lung cancer cells by negatively regulating the PI3K/Akt pathway.Scientific reports · 2018Article
- Review
- Methylation-induced downregulation and tumor suppressive role of microRNA-29b in gastric cancer through targeting LASP1.Oncotarget · 2017Article
- miR-564 is downregulated in gastric carcinoma and targets E2F3.Oncology letters · 2017Article
- MicroRNA-143-3p, up-regulated in H. pylori-positive gastric cancer, suppresses tumor growth, migration and invasion by directly targeting AKT2.Oncotarget · 2017Article
- The roles of microRNAs related with progression and metastasis in human cancers.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Review
- MiR-29c inhibits cell growth, invasion, and migration of pancreatic cancer by targeting ITGB1.OncoTargets and therapy · 2016Article
- miR-106a* inhibits the proliferation of renal carcinoma cells by targeting IRS-2.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Dysregulation of non-coding RNAs in gastric cancer.World journal of gastroenterology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
AKT2 is a crucial mediator in the tumorigenesis and thought to be an ideal target for the treatment of malignancies. Increasing evidence has also shown that microRNAs (miRNAs) could regulate or be regulated by mRNAs and they also might serve as therapeutic agencies or targets. MiR-29s (miR-29a, miR-29b and miR-29c) had been approved that they decreased in gastric cancers (GC) by targeting CCND2, MMP2 and p42.3. However, whether miR-29s would target AKT2 have not been investigated in GC. Here, we explored the relationship between miR-29s and AKT2 and found that in GC cell lines (HGC-27 and MGC-803) and GC clinical samples the decreased levels of miR-29s accompanied by increased AKT2 expression. Introduction of miR-29s into GC cells resulted in decreased AKT2 expression and decreased the ability of cancer cells invasion, so did the siRNA-AKT2. Our studies revealed that miR-29s expression is downregulated in GC and they could repress the AKT2 expression and the inactivation of AKT and GSK3beta leading to inhibit the GC cells invasion. Taken together, our findings suggested that AKT2 may be one of the targets of miR29s in gastric cancer. By increasing the expression of miR-29s or decreasing AKT2 expression may be promising in combating with GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.